The two main types of lupus are systemic lupus erythematosus (SLE), which affects organs throughout the body, and cutaneous lupus erythematosus (CLE), which is limited to the skin. SLE is by far the more common and more serious of the two, affecting an estimated 204,000 people in the United States alone. While these are the two broad categories most people encounter, lupus also has less common forms, including drug-induced lupus and neonatal lupus, each with distinct causes and outcomes.
Systemic Lupus Erythematosus (SLE)
SLE is what most people mean when they say “lupus.” It’s an autoimmune disease in which the immune system fails to clear out self-reactive immune cells, leading the body to produce antibodies that attack its own tissues. These antibodies form clusters called immune complexes that trigger inflammation and, over time, damage organs. The disease can affect nearly every system in the body, which is why it’s called “systemic.”
Joint pain and swelling are the most widespread symptoms, showing up in as many as 95% of people with SLE. Skin problems follow closely: between 70 and 80% of patients develop skin lesions at some point, most recognizably the butterfly-shaped rash across the cheeks and nose known as a malar rash. Sensitivity to sunlight is another hallmark, often triggering or worsening flares.
The kidney is the most commonly involved internal organ. Although only about half of SLE patients develop obvious kidney disease, biopsy studies reveal some degree of kidney involvement in nearly all of them. SLE also raises cardiovascular risk significantly. People with SLE face at least two to three times the risk of heart attack, heart failure, and stroke compared to the general population. For premenopausal women with SLE, the risk of heart attack jumps to 50 times higher than that of healthy women the same age. Roughly 30% of deaths in SLE patients are attributed to coronary artery disease.
Other organs are frequently affected as well. Inflammation of the lining around the lungs (pleurisy) is the most common lung-related complication, while inflammation around the heart (pericarditis) is the most common cardiac one. Neurological symptoms, ranging from headaches and cognitive fog to seizures, appear in 25 to 75% of patients.
SLE overwhelmingly affects women, with female-to-male ratios in large studies ranging from 4:1 to 11:1. Symptoms most often begin between the mid-20s and mid-30s, though men tend to be diagnosed a few years later. Diagnosis can be difficult because SLE mimics many other diseases, so doctors rely on a combination of clinical signs and blood tests. A positive antinuclear antibody (ANA) test is a starting point, and antibodies against double-stranded DNA are particularly characteristic of SLE and help distinguish it from skin-only lupus.
Cutaneous Lupus Erythematosus (CLE)
Cutaneous lupus is confined to the skin. It does not cause the widespread organ damage seen in SLE, though some people with cutaneous lupus eventually develop systemic disease. CLE is divided into three subtypes based on how the rashes look and behave: acute, subacute, and chronic.
Acute Cutaneous Lupus
Acute cutaneous lupus is most closely tied to SLE. The classic butterfly rash across the cheeks and nose falls into this category. It appears during active flares and often signals systemic involvement.
Subacute Cutaneous Lupus (SCLE)
SCLE produces ring-shaped or scaly red patches, typically on the upper chest (in a “V” pattern), upper back, and outer arms. It spares the central face, scalp, and areas below the waist. About 42% of patients develop the ring-shaped version, 39% the scaly version, and 16% show features of both. SCLE lesions are superficial and usually heal without scarring, though they can leave behind lighter or darker patches of skin. Sun sensitivity is extremely common, reported in anywhere from 27 to 100% of cases. Blood tests in SCLE patients often reveal Ro/SSA antibodies but typically lack the anti-double-stranded DNA antibodies seen in SLE, and serious kidney disease, joint inflammation, and organ-lining inflammation are far less frequent.
Discoid Lupus (Chronic CLE)
Discoid lupus erythematosus (DLE) is the most common form of chronic cutaneous lupus. It produces well-defined, thick, scaly patches primarily on the scalp, ears, and face, though generalized forms can extend to the arms and hands. Unlike SCLE, discoid lupus causes scarring. The patches can plug hair follicles, leading to permanent hair loss on the scalp, and leave behind areas of atrophy and discoloration that don’t fully recover.
Treatment for cutaneous lupus starts with high-potency topical steroid creams, which are used by roughly half of all patients. For cases that don’t respond, hydroxychloroquine (an antimalarial pill) is the standard next step, with strong evidence supporting its effectiveness. A small percentage of patients, around 4%, receive newer biologic therapies when other options fall short.
How These Two Types Relate
The distinction between SLE and cutaneous lupus is not always clean-cut. Some people diagnosed with cutaneous lupus later progress to SLE. And SLE frequently causes skin rashes, meaning many SLE patients technically have cutaneous involvement too. The key difference is whether the disease stays in the skin or extends to internal organs like the kidneys, heart, lungs, or brain. Blood work helps clarify this: SLE patients are more likely to have antibodies against double-stranded DNA, U1 RNP, and Sm proteins, while cutaneous lupus patients more often test positive for Ro/SSA antibodies without those systemic markers.
Drug-Induced Lupus
Drug-induced lupus is a lupus-like syndrome triggered by certain medications. It tends to be milder than SLE and usually resolves within a few weeks to months after stopping the responsible drug. Two older medications carry the highest risk: procainamide (a heart rhythm drug) causes lupus-like symptoms in up to 30% of users, and hydralazine (a blood pressure medication) in 5 to 10%. Biologic medications used for autoimmune conditions, certain antibiotics, anti-seizure drugs, and some blood pressure medications have also been linked to drug-induced lupus. The autoantibodies produced during drug-induced lupus can linger in the blood for years after symptoms clear, but they rarely cause ongoing problems.
Neonatal Lupus
Neonatal lupus occurs when a pregnant person’s antibodies (specifically Ro/SSA and La/SSB antibodies) cross the placenta and affect the developing baby. The mother may or may not have been diagnosed with lupus herself. Most symptoms in the newborn, such as skin rashes, are temporary and resolve as the maternal antibodies naturally clear from the baby’s system. The serious exception is cardiac involvement, which occurs in about 25% of neonatal lupus cases and most often presents as a permanent heart block that disrupts the heart’s electrical signaling.